The New Testament Era of Rosuzet and K-CAB

Cumulative ranking of outpatient prescriptions in Q3

Rosuzet's prescription amount was 103 billion won by September, recording a new quarterly record for 10 consecutive quarters

K-CAB reserves to surpass 100 billion won for the second consecutive year

Domestic developed drugs continued to be strong in the foreign prescription drug market.

 

Hanmi Pharmaceutical's complex new drug Rosuzet exceeded 100 billion won in prescriptions in three quarters, while HK inno.N's new drug K-CAB booked 100 billion won for the second consecutive year.

 

According to UBIST, a drug research institute, on the 23rd, Viatris' hyperlipidemia drug Lipitor took the lead with a cumulative outpatient prescription amount of 147.7 billion won in the third quarter of this year.

 

Although it decreased by 3.2% compared to the same period last year, it maintained a gap of more than 40 billion won with the second-ranked group and continued to take a relaxed lead.

 

Lipitor was released in Korea in 1999.

 

It has been more than 20 years since its launch in Korea, and more than 100 generics and various combinations are intensively checking Lipitor, but it still has a strong influence in the prescription drug market.

 

Lipitor has been the leader in outpatient prescriptions since 2018, and if this trend continues, it is likely to be the No.

 

1 for five consecutive years.

 

Rosuzet and K-CAB, developed by Korean companies Hanmi Pharmaceutical and HK inno.N, continued to be super strong.

 

Rosuzet ranked second overall by recording 103 billion won in cumulative prescriptions up 13.3% from the previous year until September.

 

Rosuzet, released in late 2015, is a hyperlipidemia complex composed of two ingredients, Rosuvastatin and Ezetimibe.

 

Rosuzet continues to grow rapidly due to its market preoccupation effect and the popularity of statin and Ezetimib complexes.

 

Statin and Ezetimib complex drugs show excellent effects in lowering LDL-C, and their preference is increasing because the burden of drug prices is not as high as taking two drugs separately.

 

Rosuzet is the first domestic developed drug to surpass 100 billion won in prescription in three quarters.

 

Rosuzet exceeded 100 billion won in prescription performance in 2020 and last year, and confirmed that it exceeded 100 billion won for the third consecutive year.

 

Rosuzet more than tripled in five years from 11.2 billion won in prescriptions in the third quarter of 2017 to 35.6 billion won in the third quarter of this year.

 

Rosuzet has been breaking a new quarterly prescription record for 10 consecutive quarters since it recorded 23.5 billion won in the first quarter of 2020.

 

Since June last year, the monthly prescription has been around 10 billion won for 16 consecutive months.

 

K-CAB's cumulative prescription performance in September was 92.2 billion won, up 18.0% from the previous year.

 

K-CAB, released in March 2019, is a 'P-CAB' anti-an ulcer drug.

 

In gastric wall cells, a proton pump and potassium ion located in the final stage of acid secretion are competitively combined to exhibit an action mechanism that inhibits gastric acid secretion.

 

K-CAB has a faster medicinal effect than existing PPI products and can be taken regardless of before and after meals.

 

K-CAB posted 30.9 billion won in sales in the first year of its release and surpassed 100 billion won last year, the third year of its launch.

 

K-CAB's growth slowed down from 31.5 billion won in prescription performance in the fourth quarter of last year to 30.1 billion won in the first quarter of this year, but it showed an upward trend again in the second quarter.

 

It broke a new record in three quarters, recording 31.6 billion won in prescriptions in the third quarter.

 

K-CAB sequentially secured five indications, including erosive and non-erosive gastroesophageal reflux disease, antibiotic combination therapy for Helicobacter pylori eradication in patients with gastric ulcers and chronic atrophic gastritis, and maintenance therapy after treatment for erosive gastroesophageal reflux disease.

 

Among them, health insurance benefits are being applied to gastroesophageal reflux disease and gastric ulcers.

 

It is analyzed that the demand for prescriptions has increased further as health insurance benefits have been applied to gastric ulcer treatment since November last year.

 

In the third quarter of last year, K-CAB continued to rise despite the release of Fexuclu, a P-CAB-based anti-ulcerative drug that is the same as K-CAB.

 

Fexuclu is a new drug product developed by Daewoong Pharmaceutical.

 

It was approved at the end of last year and was listed on the health insurance benefit list in July, and began selling in earnest.

 

Fexuclu became a sensation in the first quarter of its release, recording 4.5 billion won in prescriptions.

 

It posted a prescription performance of 1.1 billion won in July, and increased its increase to 1.5 billion won and 1.9 billion won, respectively, in August and September.

 

It is evaluated that Fexuclu is leading the expansion of the P-CAB-affiliated market by creating a new market or targeting the PPI-affiliated drug market without encroaching on the prescription market for the same drug.

 

Among the domestically developed drugs, Daewoong's Gliatamin, Chong Kun Dang's CKD Gliatilin, and LG Chem's Zemimet ranked at the top of the prescription.

 

Gliatamin and CKD Gliatilin, brain functional stimulants composed of Choline alfoscerate, continued to rise with accumulated prescriptions of 83.7 billion won and 72.2 billion won, respectively, in the third quarter.

 

Zemimet, a diabetes complex developed by LG Chem, ranked eighth overall in the total, recording 69.9 billion won in prescription performance, up 4.8% from the previous year, until September.

 

Zemimet is a complex that combines Metformin with Zemiglo, a DPP-4 inhibitor-based diabetes drug developed by LG Chem.

 

Daiichi Sankyo's anticoagulant Lixiana ranked in the top 10 with 66.4 billion won in the third quarter, up 6.4% from the previous year.

 

It also promoted patent-expired new drugs from multinational pharmaceutical companies such as Flavix of Sanofi Aventis and Twynsta of Beringer Ingelheim.

 

Plavix, an anti-thrombotic drug, ranked fourth overall, up 4.6% from the previous year with 88.3 billion won in prescriptions until the third quarter.

 

Plavix has joined the sale of Dong-Wha since 2017.

 

Twynsta's cumulative prescription amount in the third quarter was 70.8 billion won, up 3.0% from the previous year.